Olorofim

Olorofim
Clinical data
Other names	F901318
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-(1,5-Dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide;
CAS Number	1928707-56-5;
PubChem CID	91885568;
UNII	T34SH2H9HI;
Chemical and physical data
Formula	C28H27FN6O2
Molar mass	498.562 g·mol−1

Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections.^[1]^[2] If approved it would be a first-in-class medication (for the orotomide class). In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug.^[3] Olorofim does not inhibit growth of Candida species.^[2]

References[edit]

^ Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
^ ^a ^b Wiederhold, Nathan P. (2020). "Review of the Novel Investigational Antifungal Olorofim". Journal of Fungi. 6 (3): 122. doi:10.3390/jof6030122. ISSN 2309-608X. PMC 7557671. PMID 32751765.
^ "FDA Passes on Olorofim Despite Critical Need for Antifungals". Medscape.

[1] Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.

[Wieder-2] Wiederhold, Nathan P. (2020). "Review of the Novel Investigational Antifungal Olorofim". Journal of Fungi. 6 (3): 122. doi:10.3390/jof6030122. ISSN 2309-608X. PMC 7557671. PMID 32751765.

[3] "FDA Passes on Olorofim Despite Critical Need for Antifungals". Medscape.

[1]

[2]

[3]